{
    "Trade/Device Name(s)": [
        "EliATM B2-Glycoprotein I IgA Immunoassay",
        "EliA \u03b22-Glycoprotein I IgA"
    ],
    "Submitter Information": "Phadia AB",
    "510(k) Number": "K112414",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MSV"
    ],
    "Summary Letter Date": "June 20, 2012",
    "Summary Letter Received Date": "June 21, 2012",
    "Submission Date": "May 29, 2012",
    "Regulation Number(s)": [
        "21CFR866.5660"
    ],
    "Regulation Name(s)": [
        "Multiple autoantibodies immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "autoimmune"
    ],
    "Analyte(s)": [
        "IgA antibodies to \u03b22-Glycoprotein I"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Heparin tube",
        "EDTA tube",
        "Citrate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Phadia 100",
        "Phadia 250"
    ],
    "Method(s)/Technology(ies)": [
        "Fluorescence Immunoassay",
        "Enzyme Immunoassay (EIA)"
    ],
    "Methodologies": [
        "Immunoassay",
        "Fluorescence detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Conjugate",
        "Substrate",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for EliATM B2-Glycoprotein I IgA Immunoassay using automated fluorescence immunoassay for detection of IgA antibodies to \u03b22-Glycoprotein I in serum and plasma",
    "Indications for Use Summary": "Intended for the in vitro semi-quantitative measurement of IgA antibodies to \u03b22-Glycoprotein I in human serum and plasma to aid in the diagnosis of antiphospholipid syndrome (APS) and thrombotic disorders related to systemic lupus erythematosus (SLE), used with Phadia 100/250 instruments in conjunction with other laboratory and clinical findings",
    "fda_folder": "Immunology"
}